Bloomberg recently spoke with several doctors involved in the development of Pfizer’s new heart drug, tafamidis, who voiced their opposition to the drug’s $225,000 annual price tag, or $651 a day.
One of those doctors, Columbia University Irving Medical Center’s Mathew Maurer, during a September event said he felt the drug deserved a significantly lower price tag.
“We can agree to disagree, but I had told them I thought $25,000 a year might have been a reasonable cost,” he said.
To read the full report on Bloomberg, click here. (Paid subscription required)